Balyasny Asset Management L.P. Buys New Stake in Personalis, Inc. (NASDAQ:PSNL)

Balyasny Asset Management L.P. purchased a new position in Personalis, Inc. (NASDAQ:PSNL - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 60,127 shares of the company's stock, valued at approximately $348,000. Balyasny Asset Management L.P. owned approximately 0.09% of Personalis as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also bought and sold shares of PSNL. Stifel Financial Corp boosted its position in shares of Personalis by 25.0% during the fourth quarter. Stifel Financial Corp now owns 25,000 shares of the company's stock worth $144,000 after acquiring an additional 5,000 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Personalis by 2,827.0% in the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after purchasing an additional 5,654 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Personalis by 38.3% in the 4th quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock worth $199,000 after purchasing an additional 9,535 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its holdings in shares of Personalis by 66.6% during the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 25,168 shares of the company's stock valued at $145,000 after purchasing an additional 10,065 shares during the last quarter. Finally, Olympiad Research LP bought a new position in shares of Personalis during the 4th quarter valued at about $59,000. Hedge funds and other institutional investors own 61.91% of the company's stock.

Personalis Price Performance

Shares of NASDAQ:PSNL traded down $0.12 during trading hours on Thursday, hitting $4.60. 93,370 shares of the company's stock traded hands, compared to its average volume of 1,007,979. The firm has a market capitalization of $406.30 million, a P/E ratio of -2.75 and a beta of 1.83. The business has a fifty day moving average price of $3.84 and a 200-day moving average price of $4.46. Personalis, Inc. has a 1 year low of $1.14 and a 1 year high of $7.20.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.05. The company had revenue of $20.61 million for the quarter, compared to the consensus estimate of $17.41 million. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. As a group, equities analysts predict that Personalis, Inc. will post -1.4 earnings per share for the current year.

Analyst Ratings Changes

PSNL has been the topic of a number of research analyst reports. Guggenheim assumed coverage on Personalis in a research report on Thursday, May 15th. They issued a "buy" rating and a $6.00 target price on the stock. Craig Hallum began coverage on Personalis in a report on Monday, March 17th. They set a "buy" rating and a $8.00 price objective on the stock. Needham & Company LLC reiterated a "buy" rating and set a $7.00 target price on shares of Personalis in a research report on Thursday, April 10th. Finally, HC Wainwright upped their price target on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $7.67.

Personalis Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.